Next generation of immune checkpoint therapy in cancer: new developments and challenges

[1]  Mark W. Ball,et al.  Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma , 2018, Science.

[2]  O. Lambotte,et al.  Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Y. Lou,et al.  Cancer immunotherapy beyond immune checkpoint inhibitors , 2018, Journal of Hematology & Oncology.

[4]  J. Schlom,et al.  Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors , 2018, Clinical Cancer Research.

[5]  K. Flaherty,et al.  Mechanisms of resistance to immune checkpoint inhibitors , 2018, British Journal of Cancer.

[6]  B. Besse,et al.  Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  L. Zitvogel,et al.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications , 2017, Oncoimmunology.

[8]  M. Smyth,et al.  Targeting immunosuppressive adenosine in cancer , 2017, Nature Reviews Cancer.

[9]  A. Levine,et al.  A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy , 2017, Nature.

[10]  M. Fornai,et al.  Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. , 2017, Drug discovery today.

[11]  M. Smyth,et al.  Targeting immunosuppressive adenosine in cancer , 2017, Nature Reviews Cancer.

[12]  A. Bensussan,et al.  Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas , 2017, Front. Immunol..

[13]  I. Melero,et al.  Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy , 2017, Clinical Cancer Research.

[14]  I. Castaneda,et al.  A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect , 2017, Journal of hepatocellular carcinoma.

[15]  E. Tartour,et al.  Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer , 2017, ESMO Open.

[16]  S. Loi,et al.  Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors , 2017 .

[17]  R. Sullivan,et al.  Abstract CT089: IPI-549-01 - A Phase 1/1b, first-in-human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors , 2017 .

[18]  J. Zha,et al.  Abstract CT091: Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors , 2017 .

[19]  J. Desai,et al.  Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial , 2017 .

[20]  C. Sarisozen,et al.  Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller? , 2017 .

[21]  Maheedhara R. Guda,et al.  B7-H3 role in the immune landscape of cancer. , 2017, American journal of clinical and experimental immunology.

[22]  S. Whittaker,et al.  Phase I Study of IPH4102, Anti‐KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T‐Cell Lymphomas (CTCL): Dose‐escalation Safety, Biomarker and Clinical Activity Results , 2017 .

[23]  M. Brown,et al.  An open-label, multi-center phase I study of the safety and tolerability of the novel immunomodulatory agent PG545 in subjects with advanced solid tumors. , 2017 .

[24]  J. Burke,et al.  Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC. , 2017 .

[25]  S. Granjeaud,et al.  HVEM: A novel cosignaling molecule of major interest in melanoma. , 2017 .

[26]  P. Ascierto,et al.  Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. , 2017 .

[27]  David C. Smith,et al.  Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037. , 2017 .

[28]  F. Janku,et al.  PEGylated human IL-10 (AM0010) in combination with pembrolizumab in anti-PD1 and CTLA-4 refractory melanoma. , 2017 .

[29]  J. Schlom,et al.  Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors. , 2017 .

[30]  M. Hurwitz,et al.  Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy. , 2017 .

[31]  M. Hurwitz,et al.  A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors. , 2017 .

[32]  J. Spicer,et al.  LTX-315, an oncolytic peptide, to convert immunogenically ‘cold' tumors to ‘hot' in patients with advanced or metastatic tumours: Results from an ongoing phase I study. , 2017 .

[33]  J. Berlin,et al.  Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204. , 2017 .

[34]  A. Korman,et al.  Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors. , 2017 .

[35]  J. Koopmeiners,et al.  A phase II randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC). , 2017 .

[36]  K. Papadopoulos,et al.  CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients (pts) with solid tumors. , 2017 .

[37]  E. Rasmussen,et al.  Dose escalation results from a first-in-human, phase 1 study of the glucocorticoid-induced TNF receptor-related protein (GITR) agonist AMG 228 in patients (Pts) with advanced solid tumors. , 2017 .

[38]  O. Akilov,et al.  A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides. , 2017 .

[39]  B. Sveinbjørnsson,et al.  LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment. , 2017, Future medicinal chemistry.

[40]  K. Weiskopf.  Cancer immunotherapy targeting the CD47/SIRPα axis. , 2017, European journal of cancer.

[41]  R. Gordon,et al.  Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer , 2017, Asia-Pacific journal of oncology nursing.

[42]  I. Melero,et al.  Targeting NK-cell checkpoints for cancer immunotherapy. , 2017, Current opinion in immunology.

[43]  R. Ferris,et al.  TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action , 2017, International journal of molecular sciences.

[44]  M. Cragg,et al.  OX40: Structure and function - What questions remain? , 2017, Molecular immunology.

[45]  C. Drake,et al.  LAG3 (CD223) as a cancer immunotherapy target , 2017, Immunological reviews.

[46]  W. Dempke,et al.  Second- and third-generation drugs for immuno-oncology treatment-The more the better? , 2017, European journal of cancer.

[47]  P. Hawkins,et al.  Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment , 2017, Cancers.

[48]  Yingwei Xue,et al.  Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis , 2017, OncoTargets and therapy.

[49]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[50]  M. Shi,et al.  Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways , 2017, International journal of molecular sciences.

[51]  Zihai Li,et al.  Is CD47 an innate immune checkpoint for tumor evasion? , 2017, Journal of Hematology & Oncology.

[52]  P. O'dwyer,et al.  First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies , 2017, Clinical Cancer Research.

[53]  William A. Hammond,et al.  Emerging therapeutic agents for lung cancer , 2016, Journal of Hematology & Oncology.

[54]  J. Brogdon,et al.  Rationale for anti-GITR cancer immunotherapy. , 2016, European journal of cancer.

[55]  Y. Nishio,et al.  Abstract A101: Role of TIM-3/Galectin-9 pathway in lung cancer , 2016 .

[56]  You-Wen He,et al.  Interleukin-10: An Immune-Activating Cytokine in Cancer Immunotherapy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  R. Levy,et al.  Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody , 2016, Clinical Cancer Research.

[58]  F. Hirsch,et al.  Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer , 2016, Cancer science.

[59]  A. Brandes,et al.  A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. , 2016, Neuro-oncology.

[60]  H. Gogas,et al.  Toxicity management of immunotherapy for patients with metastatic melanoma. , 2016, Annals of translational medicine.

[61]  N. Rizvi,et al.  Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events , 2016 .

[62]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[63]  Y. Li,et al.  Application potential of toll-like receptors in cancer immunotherapy , 2016, Medicine.

[64]  T. Jiang,et al.  Role of IL-2 in cancer immunotherapy , 2016, Oncoimmunology.

[65]  I. Weissman,et al.  First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  X. Zang,et al.  Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy , 2016, Clinical Cancer Research.

[67]  P. Pauwels,et al.  Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE Antibody ARGX-110. , 2016 .

[68]  L. Chow,et al.  A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors. , 2016 .

[69]  D. Munn,et al.  Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma. , 2016 .

[70]  B. Somer,et al.  Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: Interim analysis. , 2016 .

[71]  J. Wolchok,et al.  First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors. , 2016 .

[72]  D. Nuyten,et al.  First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results. , 2016 .

[73]  A. Tolcher,et al.  Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature. , 2016 .

[74]  E. Schmidt,et al.  Phase Ib study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors. , 2016 .

[75]  K. Ng,et al.  OT-101: An anti-TGF-beta-2 antisense- primed tumors to subsequent chemotherapies. , 2016 .

[76]  Ana C Anderson,et al.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.

[77]  A. Mansell,et al.  Toll-like receptors: the swiss army knife of immunity and vaccine development , 2016, Clinical & translational immunology.

[78]  M. Vetizou,et al.  The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade , 2016, Cell Death and Differentiation.

[79]  P. Chanson,et al.  Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[80]  H. Kohrt,et al.  4-1BB agonism: adding the accelerator to cancer immunotherapy , 2016, Cancer Immunology, Immunotherapy.

[81]  M. Kovář,et al.  IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy? , 2016, Oncoimmunology.

[82]  L. Zitvogel,et al.  The oncolytic peptide LTX-315 triggers immunogenic cell death , 2016, Cell Death and Disease.

[83]  P. Romero.  Journal for immunotherapy of cancer reviewer acknowledgement 2015 , 2016, Journal of Immunotherapy for Cancer.

[84]  Jing Wang,et al.  Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma , 2016, Clinical Cancer Research.

[85]  P. Hwu,et al.  Targeting the indoleamine 2,3-dioxygenase pathway in cancer , 2015, Journal of Immunotherapy for Cancer.

[86]  E. Alici,et al.  Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity , 2015, Front. Immunol..

[87]  E. Ananieva.  Targeting amino acid metabolism in cancer growth and anti-tumor immune response. , 2015, World journal of biological chemistry.

[88]  Kutlu G. Elpek,et al.  Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics , 2015, Journal of Immunotherapy for Cancer.

[89]  K. Flaherty,et al.  Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 , 2015, Journal of Immunotherapy for Cancer.

[90]  A. Goldrath,et al.  IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapy , 2015, Science Translational Medicine.

[91]  Kyung-Jin Cho,et al.  Interleukin 10 (IL-10)-mediated Immunosuppression , 2015, The Journal of Biological Chemistry.

[92]  E. Loftus,et al.  Systematic review: colitis associated with anti‐CTLA‐4 therapy , 2015, Alimentary pharmacology & therapeutics.

[93]  I. Melero,et al.  Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. , 2015, Seminars in oncology.

[94]  J. Borst,et al.  Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. , 2015, Immunotherapy.

[95]  R. Johnston,et al.  The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+ T cell responses , 2015, Oncoimmunology.

[96]  Joe-Marc Chauvin,et al.  TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. , 2015, The Journal of clinical investigation.

[97]  Joe-Marc Chauvin,et al.  IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. , 2015, Cancer research.

[98]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[99]  J. Powell,et al.  A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy , 2015, Computational and structural biotechnology journal.

[100]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[101]  L. Zitvogel,et al.  Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications , 2015, Oncoimmunology.

[102]  Jérôme Cros,et al.  Targeting the TGFβ pathway for cancer therapy. , 2015, Pharmacology & therapeutics.

[103]  M. Mcnamara,et al.  OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal , 2015, Front. Oncol..

[104]  L. Nguyen,et al.  Clinical blockade of PD1 and LAG3 — potential mechanisms of action , 2014, Nature Reviews Immunology.

[105]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[106]  U. Brinkmann,et al.  Tumor-antigen-binding bispecific antibodies for cancer treatment. , 2014, Seminars in oncology.

[107]  A. Ebrahim,et al.  Galectins in cancer: carcinogenesis, diagnosis and therapy. , 2014, Annals of translational medicine.

[108]  L. Sempere,et al.  VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy , 2014, Cancer Immunology Research.

[109]  P. Sharma,et al.  Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy , 2014, The Journal of experimental medicine.

[110]  R. Noelle,et al.  VISTA Regulates the Development of Protective Antitumor Immunity. , 2014, Cancer research.

[111]  M. Ernstoff,et al.  VISTA is an immune checkpoint molecule for human T cells. , 2014, Cancer research.

[112]  J. Harty,et al.  Tim-3 Directly Enhances CD8 T Cell Responses to Acute Listeria monocytogenes Infection , 2014, The Journal of Immunology.

[113]  Hailing Lu.  TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects , 2014, Front. Immunol..

[114]  M. Caligiuri,et al.  Killer Immunoglobulin-like Receptors and Tumor Immunity , 2014, Cancer Immunology Research.

[115]  B. Fox,et al.  OX40 is a potent immune-stimulating target in late-stage cancer patients. , 2013, Cancer research.

[116]  Jonathan B. Mitchem,et al.  A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma , 2013, Investigational New Drugs.

[117]  Jenna M. Sullivan,et al.  TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer , 2013, Oncoimmunology.

[118]  Lieping Chen,et al.  Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.

[119]  M. Glennie,et al.  Agonistic CD40 Antibodies and Cancer Therapy , 2013, Clinical Cancer Research.

[120]  H. Ford,et al.  Molecular Pathways Molecular Pathways : Targeting the TGF-b Pathway for Cancer Therapy , 2012 .

[121]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[122]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[123]  Peter Vogel,et al.  Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .

[124]  Heidi Ledford.  Melanoma drug wins US approval , 2011, Nature.

[125]  M. Moser,et al.  Role of CD27/CD70 pathway of activation in immunity and tolerance , 2011, Journal of leukocyte biology.

[126]  M. Zaaroor,et al.  Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study , 2010, Neuro-oncology.

[127]  M. Pedriali,et al.  CD8+ T cells expressing IL-10 are associated with a favourable prognosis in lung cancer. , 2010, Lung cancer.

[128]  Bin Zhang.  CD73: a novel target for cancer immunotherapy. , 2010, Cancer research.

[129]  M. Gutiérrez,et al.  First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity , 2010, Journal of Translational Medicine.

[130]  M. Smyth,et al.  Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules , 2010, The Journal of Immunology.

[131]  J. Humm,et al.  Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma , 2010, Journal of Neuro-Oncology.

[132]  C. June,et al.  Putting the brakes on BTLA in T cell-mediated cancer immunotherapy. , 2010, The Journal of clinical investigation.

[133]  N. Stanietsky,et al.  The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity , 2009, Proceedings of the National Academy of Sciences.

[134]  B. Escudier,et al.  A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma , 2009, Clinical Cancer Research.

[135]  G. Pawelec,et al.  Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines , 2009, Cancer Immunology, Immunotherapy.

[136]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[137]  R. Vonderheide.  Prospect of Targeting the CD40 Pathway for Cancer Therapy , 2007, Clinical Cancer Research.

[138]  V. Kuchroo,et al.  The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity , 2005, Nature Immunology.

[139]  J. Massagué,et al.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. , 2005, Cancer cell.

[140]  D. Vignali,et al.  Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-31 , 2002, The Journal of Immunology.

[141]  D. F. Barber,et al.  Inhibition of natural killer cell activation signals by killer cell immunoglobulin‐like receptors (CD158) , 2001, Immunological reviews.

[142]  Hua Yu,et al.  Anti-CD40 Antibody Induces Antitumor and Antimetastatic Effects: The Role of NK Cells1 , 2001, The Journal of Immunology.

[143]  J. Blay,et al.  Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial , 2018, JAMA oncology.

[144]  V. Cerundolo,et al.  Modulation of cancer-specific immune responses by amino acid degrading enzymes. , 2017, Immunotherapy.

[145]  L. Zitvogel,et al.  Rationale for anti-OX40 cancer immunotherapy. , 2016, European journal of cancer.

[146]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[147]  David C. Smith,et al.  First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70 , 2015, Cancer Chemotherapy and Pharmacology.

[148]  Charles G. Drake,et al.  Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer , 2014, Nature Reviews Clinical Oncology.

[149]  M. Magnani,et al.  The expression and modulation of CEACAM1 and tumor cell transformation. , 2012, Annali dell'Istituto superiore di sanita.

[150]  C. Drake,et al.  LAG-3 in Cancer Immunotherapy. , 2011, Current topics in microbiology and immunology.

[151]  Michael K. Wendt,et al.  Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression , 2011, Cell and Tissue Research.

[152]  H. Clark,et al.  The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells , 2009, Nature Immunology.

[153]  David Padua,et al.  Roles of TGFβ in metastasis , 2009, Cell Research.